Ziouti Fani, Rummler Maximilian, Steyn Beatrice, Thiele Tobias, Seliger Anne, Duda Georg N, Bogen Bjarne, Willie Bettina M, Jundt Franziska
Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany.
Research Centre, Shriners Hospital for Children-Canada, Montreal, QC H4A 0A9, Canada.
Int J Mol Sci. 2021 Apr 7;22(8):3840. doi: 10.3390/ijms22083840.
Limiting bone resorption and regenerating bone tissue are treatment goals in myeloma bone disease (MMBD). Physical stimuli such as mechanical loading prevent bone destruction and enhance bone mass in the MOPC315.BM.Luc model of MMBD. It is unknown whether treatment with the Bruton's tyrosine kinase inhibitor CC-292 (spebrutinib), which regulates osteoclast differentiation and function, augments the anabolic effect of mechanical loading. CC-292 was administered alone and in combination with axial compressive tibial loading in the MOPC315.BM.Luc model for three weeks. However, neither CC-292 alone nor its use in combination with mechanical loading was more effective in reducing osteolytic bone disease or rescuing bone mass than mechanical stimuli alone, as evidenced by microcomputed tomography (microCT) and histomorphometric analysis. Further studies are needed to investigate novel anti-myeloma and anti-resorptive strategies in combination with physical stimuli to improve treatment of MMBD.
限制骨吸收和再生骨组织是骨髓瘤骨病(MMBD)的治疗目标。在MMBD的MOPC315.BM.Luc模型中,诸如机械负荷等物理刺激可防止骨质破坏并增加骨量。尚不清楚调节破骨细胞分化和功能的布鲁顿酪氨酸激酶抑制剂CC-292(司布替尼)治疗是否会增强机械负荷的合成代谢作用。在MOPC315.BM.Luc模型中,单独给予CC-292并将其与轴向胫骨压缩负荷联合应用三周。然而,如显微计算机断层扫描(microCT)和组织形态计量学分析所示,单独使用CC-292或其与机械负荷联合使用在减少溶骨性骨病或恢复骨量方面并不比单独的机械刺激更有效。需要进一步研究以探索结合物理刺激的新型抗骨髓瘤和抗吸收策略,以改善MMBD的治疗。